No photo of Aparna Kalyan

View Scopus Profile

Aparna Kalyan

  • 511 Citations
20142021
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

My primary interests are in developing novel therapeutic combinations for the treatment of gastrointestinal cancers. I am interested in incorporating immunotherapy and molecular testing into clinical trials.

Training Experience

2009Residency, St. Vincents Hospital, Melbourne Australia
2011Residency, University Hospitals Case Medical Center, Cleveland OH
2014Fellowship, University of Pittsburgh Medical Center
2014Fellowship, Northwestern University

Education/Academic qualification

MBBS, Flinders University of South Australia, Australia

… → 2005

Research interests

  • Cancer Biology
  • Colon / Rectal Cancer
  • Nanotechnology
  • Pancreatic Cancer

Fingerprint Dive into the research topics where Aparna Kalyan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles
Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Biliary Tract Neoplasms Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Fibroblast Growth Factor Receptors Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Hepatocellular Carcinoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2015 2021

Prot #H3B-6527-G000-101: An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Kalyan, A.

PPD Investigator Services, LLC, H3 Biomedicine Inc.

2/14/18 → 2/14/21

Project: Research project

Prot #AG120-C-005: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

Kalyan, A.

DrugDev Inc., Agios Pharmaceuticals, Inc.

1/25/18 → 1/25/21

Project: Research project

Prot #NC-6004-004A: A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Bladder Cancer

Kalyan, A.

PPD Investigator Services, LLC, NanoCarrier Co., Ltd.

8/29/17 → 8/29/20

Project: Research project

Prot #ABI-007-PANC-009: An Open-Label, Multicenter, Single-Arm, Phase 1/2 Study Of Metronomic 5-Fluorouracil In Combination With Nabpaclitaxel, Bevacizumab, Leucovorin, And Oxaliplatin In Patients With Metastatic Pancreatic Adenocarcinoma

Kalyan, A.

INC Research, LLC, Celgene Corporation

8/10/16 → 8/10/19

Project: Research project

Prot #ABI-007-ST-001: A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or

Kalyan, A.

PPD Development, Celgene Corporation

11/11/15 → 11/11/18

Project: Research project

Research Output 2014 2019

  • 511 Citations
  • 15 Article
  • 7 Review article
  • 3 Comment/debate
  • 1 Editorial

A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation

Kamath, S. D., Lin, X. & Kalyan, A., Feb 1 2019, In : Oncologist. 24, 2, p. 151-156 6 p.

Research output: Contribution to journal › Article

Biliary Tract Neoplasms
Mutation
Adenocarcinoma
Neoplasms
Paraffin

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Kim, S. B., Meric-Bernstam, F., Kalyan, A., Babich, A., Liu, R., Tanigawa, T., Sommer, A., Osada, M., Reetz, F., Laurent, D., Wittemer-Rump, S. & Berlin, J., Oct 1 2019, In : Targeted Oncology. 14, 5, p. 591-601 11 p.

Research output: Contribution to journal › Article

Open Access
Receptor, Fibroblast Growth Factor, Type 2
Maximum Tolerated Dose
Antibodies
Pharmaceutical Preparations
Neoplasms
2 Citations (Scopus)

Piloting a financial counseling intervention for patients with cancer receiving chemotherapy

Kircher, S. M., Yarber, J., Rutsohn, J., Guevara, Y., Lyleroehr, M., Jackson, H. A., Walradt, J., Desai, B., Mulcahy, M. F., Kalyan, A., Benson III, A. B., Agulnik, M., Mohindra, N. A., DeSouza, J. & Garcia, S. F., Mar 1 2019, In : Journal of oncology practice. 15, 3, p. E202-E210

Research output: Contribution to journal › Article

Counseling
Drug Therapy
Neoplasms
Costs and Cost Analysis
Workflow
1 Citation (Scopus)

Pembrolizumab for the treatment of gastric cancer

Kamath, S. D., Kalyan, A. & Benson III, A. B., Dec 2 2018, In : Expert review of anticancer therapy. 18, 12, p. 1177-1187 11 p.

Research output: Contribution to journal › Article

Stomach Neoplasms
Immunotherapy
Stomach
Dysbiosis
Therapeutics
19 Citations (Scopus)

Updates on immunotherapy for colorectal cancer

Kalyan, A., Kircher, S., Shah, H., Mulcahy, M. & Benson, A., Feb 1 2018, In : Journal of Gastrointestinal Oncology. 9, 1, p. 160-169 10 p.

Research output: Contribution to journal › Review article

Immunotherapy
Colorectal Neoplasms
Active Immunotherapy
Standard of Care
Microsatellite Repeats